- Home
- GSIW vs EVAX Comparison
GSIW vs EVAX Comparison
Compare GSIW & EVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GSIW
- EVAX
- Stock Information
- Founded
- GSIW 2016
- EVAX 2008
- Country
- GSIW Hong Kong
- EVAX Denmark
- Employees
- GSIW N/A
- EVAX N/A
- Industry
- GSIW
- EVAX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- GSIW
- EVAX Health Care
- Exchange
- GSIW Nasdaq
- EVAX Nasdaq
- Market Cap
- GSIW 8.6M
- EVAX 8.7M
- IPO Year
- GSIW 2023
- EVAX 2021
- Fundamental
- Price
- GSIW $0.44
- EVAX $2.75
- Analyst Decision
- GSIW
- EVAX Strong Buy
- Analyst Count
- GSIW 0
- EVAX 3
- Target Price
- GSIW N/A
- EVAX $33.33
- AVG Volume (30 Days)
- GSIW 401.6K
- EVAX 6.8M
- Earning Date
- GSIW 12-31-2024
- EVAX 03-26-2025
- Dividend Yield
- GSIW N/A
- EVAX N/A
- EPS Growth
- GSIW N/A
- EVAX N/A
- EPS
- GSIW N/A
- EVAX N/A
- Revenue
- GSIW $1,313,795.00
- EVAX $3,295,000.00
- Revenue This Year
- GSIW N/A
- EVAX $4,845.21
- Revenue Next Year
- GSIW N/A
- EVAX $30.30
- P/E Ratio
- GSIW N/A
- EVAX N/A
- Revenue Growth
- GSIW N/A
- EVAX N/A
- 52 Week Low
- GSIW $0.43
- EVAX $2.22
- 52 Week High
- GSIW $15.45
- EVAX $23.70
- Technical
- Relative Strength Index (RSI)
- GSIW 33.32
- EVAX 41.09
- Support Level
- GSIW $0.43
- EVAX $2.22
- Resistance Level
- GSIW $0.51
- EVAX $4.05
- Average True Range (ATR)
- GSIW 0.06
- EVAX 1.17
- MACD
- GSIW -0.01
- EVAX 0.00
- Stochastic Oscillator
- GSIW 3.25
- EVAX 6.99
About GSIW Garden Stage Limited
Garden Stage Ltd is a Hong Kong-based financial services provider principally engaged in the provision of placing and underwriting services; securities dealing and brokerage services; and asset management services. Its business is carried out through its wholly owned Operating Subsidiaries: a) I Win Securities, which is licensed to conduct Type 1 (dealing in securities) regulated activities under the SFO in Hong Kong, and b) I Win Asset Management, which is licensed to conduct Type 4 (advising on securities) and Type 9 (asset management) regulated activities under the SFO in Hong Kong.
About EVAX Evaxion Biotech
Evaxion Biotech AS is a clinical-stage biotech company that aspires to the exploration of artificial intelligence, or AI, to develop immunotherapies with improved efficacy when compared to currently marketed products for patients with unmet medical needs. Its pipeline programs are derived from its proprietary AI platforms, PIONEER, EDEN, RAVEN, and ObsERV. The company is utilizing these AI platforms to build a drug development pipeline. Its product candidates are; EVX-01 and EVX-02, for the treatment of various cancers, and the third candidate is cancer immunotherapy, EVX-03, for the treatment of various cancers including non-small-cell-lung-cancer, or NSCLC, is in pre-clinical development.